.Consultation Deadlines

6th April 2020

FDA draft guidance for industry entitled “Promotional Labeling and Advertising Considerations for Prescription Biological Reference and Biosimilar Products—Questions and Answers.”


eipg-thumb
7th April 2020

FDA draft guidance for industry entitled “Biosimilars and Interchangeable Biosimilars: Licensure for Fewer Than All Conditions of Use for Which the Reference Product Has Been Licensed.”


eipg-thumb
7th April 2020

EMA Scientific guideline: Reflection paper on good manufacturing practice and marketing authorisation holders, draft: consultation open.


eipg-thumb
20th April 2020

FDA draft guidance entitled “Nonclinical Safety Evaluation of the Immunotoxic Potential of Drugs and Biologics.”


eipg-thumb
30th April 2020

EMA Scientific guideline: CVMP reflection paper on promoting the authorisation of alternatives to antimicrobials in the EU, draft: consultation open.


eipg-thumb
5th May 2020

FDA draft guidance for industry entitled “Mucopolysaccharidosis Type III (Sanfilippo Syndrome): Developing Drugs for Treatment.”


eipg-thumb
20th May 2020

European Commission second targeted stakeholders’ consultation on the revision of Annex 1, on manufacturing of sterile medicinal products, of Eudralex volume 4.